Abbott shines on getting nod from DCGI for once-a-day formulation ‘Ivabradine’

03 Sep 2020 Evaluate

Abbott India is currently trading at Rs. 16561.00, up by 171.80 points or 1.05% from its previous closing of Rs. 16389.20 on the BSE.

The scrip opened at Rs. 16400.00 and has touched a high and low of Rs. 16574.80 and Rs. 16318.35 respectively. So far 118 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 18569.00 on 04-May-2020 and a 52 week low of Rs. 9180.05 on 03-Sep-2019.

Last one week high and low of the scrip stood at Rs. 17249.00 and Rs. 16040.50 respectively. The current market cap of the company is Rs. 35056.99 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 7.32% and 17.69% respectively.

Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks.

Abbott India is healthcare company that discovers, develops, manufactures and markets innovative products and services.

Abbott India Share Price

26470.00 0.05 (0.00%)
16-Feb-2026 12:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1695.50
Dr. Reddys Lab 1267.40
Cipla 1350.00
Zydus Lifesciences 906.50
Lupin 2220.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×